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Abstract
Interpretation of variants present in complete genomes or exomes reveals
numerous sequence changes, only a fraction of which are likely to be
pathogenic. Mutations have been traditionally inferred from allele frequencies
and inheritance patterns in such data. Variants predicted to alter mRNA splicing
can be validated by manual inspection of transcriptome sequencing data,
however this approach is intractable for large datasets. These abnormal mRNA
splicing patterns are characterized by reads demonstrating either exon
skipping, cryptic splice site use, and high levels of intron inclusion, or
combinations of these properties. We present, Veridical, an in silico method for
the automatic validation of DNA sequencing variants that alter mRNA splicing.
Veridical performs statistically valid comparisons of the normalized read counts
of abnormal RNA species in mutant versus non-mutant tissues. This leverages
large numbers of control samples to corroborate the consequences of
predicted splicing variants in complete genomes and exomes.
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REVISED Amendments from Version 1
      
We appreciate the feedback received from the reviewers and
we feel that the manuscript has been improved as a result. The
following major revisions have been incorporated:
•
•
•

•

•
•

Figure 1 has been abbreviated according to the advice of the
reviewers.
Figure 2 is new. It illustrates the details of the data used to
infer different types of splicing events.
We have re-formulated the equations in the methods section
pertaining to the definitions of the various validating reads,
as requested by reviewers, and we reference each formal
definition in the text.
We have clearly demarcated the performance information
and have added sub-headings to improve the readability of
our results section.
We have coloured all mutant reads in the IGV images to more
clearly depict every validating read and its type.
We have added paragraphs to the Discussion pertaining to:
○ Achieving sample size sufficiency via power analysis
○ Clarifying that Veridical does not attempt to predict
alternative splicing events
○ Clarifying our usage of the term “validation”

We have also updated the Veridical software, as follows:
It now outputs p-values to four (instead of two) decimal places.
This allows for more precise post-hoc filtering and can allow one to
apply more stringent thresholds, as recently advocated (Johnson
Proc. Natl. Acad. Sci. 110: 19313–7, 2013).
The correct behavior of allowing a variant to be present in the
filtered set is to check if there are any strongly corroborating,
statistically significant, results. Previously, the filtered output file
would only consider the p-value of the splicing consequence of
highest frequency. This has been fixed.
Strongly corroborating reads are defined as: any junctionspanning-based evidence or read-abundance-based intron
inclusion (refer to the manuscript for more details).
We noticed that variants with a statistically significant number of
intron inclusion with mutation reads were erroneously placed into
the filtered set, despite the overall number of intron inclusion reads
not having achieved statistical significance. We have resolved this
regression.
None of the changes to Veridical, nor the aforementioned
regressions, affected any of the results presented in our
manuscript. For a more detailed explanation of the revisions made
please refer to the referees’ comments and our respective replies.
See referee reports

Introduction
DNA variant analysis of complete genome or exome data has typically relied on filtering of alleles according to population frequency
and alterations in coding of amino acids. Numerous variants of
unknown significance (VUS) in both coding and non-coding gene
regions cannot be categorized with these approaches. To address
these limitations, in silico methods that predict biological impact of
individual sequence variants on protein coding and gene expression
have been developed, which exhibit varying degrees of sensitivity
and specificity1. These approaches have generally not been capable
of objective, efficient variant analysis on a genome-scale.
Splicing variants, in particular, are known to be a significant cause
of human disease2–5 and indeed have even been hypothesized to

be the most frequent cause of hereditary disease6. Computational
identification of mRNA splicing mutations within DNA sequencing (DNA-Seq) data has been implemented to varying degrees of
sensitivity, with most software only evaluating conservation solely
at the intronic dinucleotides adjacent to the junction (i.e.7). Other
approaches are capable of detecting significant mutations at other
positions with constitutive, and in certain instances, cryptic, splice
sites5,8,9 which can result in aberrations in mRNA splicing. Presently,
only information theory-based mRNA splicing mutation analysis
has been implemented on a genome scale10. Splicing mutations can
abrogate recognition of natural, constitutive splice sites (inactivating mutation), weaken their binding affinity (leaky mutation), or
alter splicing regulatory protein binding sites that participate in
exon definition. The abnormal molecular phenotypes of these mutations comprise: (a) complete exon skipping, (b) reduced efficiency
of splicing, (c) failure to remove introns (also termed intron retention or intron inclusion), or (d) cryptic splice site activation, which
may define abnormal exon boundaries in transcripts using nonconstitutive, proximate sequences, extending or truncating the exon.
Some mutations may result in combinations of these molecular
phenotypes. Nevertheless, novel or strengthened cryptic sites can
be activated independently of any direct effect on the corresponding
natural splice site. The prevalence of these splicing events has been
determined by ourselves and others5,11–13. The diversity of possible
molecular phenotypes makes such aberrant splicing challenging to
corroborate at the scale required for complete genome (or exome)
analyses. This has motivated the development of statistically robust
algorithms and software to comprehensively validate the predicted
outcomes of splicing mutation analysis.
Putative splicing variants require empirical confirmation based on
expression studies from appropriate tissues carrying the mutation,
compared with control samples lacking the mutation. In mutations
identified from complete genome or exome sequences, corresponding transcriptome analysis based on RNA sequencing (RNA-Seq)
is performed to corroborate variants predicted to alter splicing.
Manually inspecting a large set of splicing variants of interest with
reference to the experimental samples’ RNA-Seq data in a program
like the Integrative Genomics Viewer (IGV)14, or simply performing database searches to find existing evidence would be timeconsuming for large-scale analyses. Checking control samples
would be required to ensure that the variant is not a result of alternative splicing, but is actually causally linked to the variant of interest.
Manual inspection of the number of control samples required for statistical power to verify that each displays normal splicing would be
laborious and does not easily lend itself to statistical analyses. This
may lead to either missing contradictory evidence or to discarding a
variant due to the perceived observation of statistically insignificant
altered splicing within control samples. In addition, a list of putative splicing variants returned by variant prediction software can
often be extremely large. The validation of such a significant quantity of variants may not be feasible, for example, in certain types of
cancer, in instances where the genomic mutational load is high and
only manual annotation is performed. We have therefore developed
Veridical, a software program that automatically searches all given
experimental and control RNA-Seq data to validate DNA-derived
splicing variants. When adequate expression data are available at the
locus carrying the mutation, this approach reveals a comprehensive
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set of genes exhibiting mRNA splicing defects in complete genomes
and exomes. Veridical and its associated software programs are
available at: www.veridical.org.

Methods
The program Veridical was developed to allow high-throughput validation of predicted splicing mutations using RNA sequencing data.
Veridical requires at least three files to operate: a DNA variant file
containing putative mRNA splicing mutations, a file listing of corresponding transcriptome (RNA-Seq) BAM files, and a file annotating exome structure. A separate file listing RNA-Seq BAM files for
control samples (i.e. normal tissue) can also be provided. Here, we
demonstrate the capabilities of the software for mutations predicted
in a set of breast tumours. Veridical compares RNA-Seq data from
the same tumours with RNA-Seq data from control samples lacking the predicted mutation. However, in principle, potential splicing
mutations for any disease state with available RNA-Seq data can be
investigated. In each tumour, every variant is analyzed by checking
the informative sequencing reads from the corresponding RNA-Seq
experiment for non-constitutive splice isoforms, and comparing
these results with the same type of data from all other tumour and
normal samples that do not carry the variant in their exomes.
Veridical concomitantly evaluates control samples, providing for
an unbiased assessment of splicing variants of potentially diverse
phenotypic consequences. Note that control samples include all
non-variant containing files (i.e. RNA-Seq files for those tumours
without the variant of interest), as well any normal samples provided. Increasing the number of the set of control samples, while
computationally more expensive, increases the statistical robustness of the results obtained.
For each variant, Veridical directly analyzes sequence reads aligned
to the exons and introns that are predicted to be affected by the
genomic variant. We elected to avoid indirect measures of exon
skipping, such as loss of heterozygosity in the transcript, because
of the possibility of confusion with other molecular etiologies (i.e.
deletion or gene conversion), unrelated to the splicing mutations.
The nearest natural site is found using the exome annotation file
provided, based upon the directionality of the variant, as defined
within Table 1. The genomic coordinates of the neighboring exon
boundaries are then found and the program proceeds, iterating
over all known transcript variants for the given gene. A diagram
of this procedure is provided in Figure 1. The variant location,
Pertinent Splice Site
A

B

Strand

Direction

Exonic

Donor

+

→

Exonic

Donor

-

←

Intronic

Acceptorβ

+

←

Intronic

Acceptor

-

→

α

α
α

β

– 5′ splice site                         – 3′ splice site    
β

Table 1. Definitions used within Veridical to
determine the direction in which reads are
checked. A and B represent natural site positions,
defined in Figure 1(B).

( )

( )

blue

red

Figure 1. Diagram portraying the definitions used within Veridical to
specify genic variant position and read coordinates. We employ the
same conventions as IGV14. Blue lines denote genes, wherein thick
lines represent exons and thin lines represent introns.

C, is specifically referring to the variant itself. JC refers to the
variant-induced location of the predicted mRNA splice site, which
is often proximate to, but distinct from the coordinate of the actual
genomic mutation itself.
The program uses the BamTools API15 to iterate over all of the
reads within a given genomic region across experimental and control samples. Individual reads are then assessed for their corroborating value towards the analysis of the variant being processed,
as outlined in the flowchart in Figure 3. Validating reads are based
on whether they alter either the location of the splice junction (i.e.
junction-spanning) or the abundance of the transcript, particularly
in intronic regions (i.e. read-abundance). Junction-spanning reads
contain DNA sequences from two adjacent exons or are reads that
extend into the intron (Equation 1(e)). These reads directly show
whether the intronic sequence is removed or retained by the spliceosome, respectively. Read-abundance validated reads are based
upon sequences predicted to be found in the mutated transcript in
comparison with sequences that are expected to be excised from
the mature transcript in the absence of a mutation (Equation 1(f)).
Both types of reads can be used to validate cryptic splicing, exon
skipping, or intron inclusion. A read is said to corroborate cryptic
splicing if and only if the variant under consideration is expected to
activate cryptic splicing. Junction-spanning, cryptic splicing reads
are those in which a read is exactly split from the cryptic splice site
to the adjacent exon junction (Equation 1(a)). For read-abundance
cryptic splicing, we define the concept of a read fraction, which
is the ratio of the number of reads corroborating the cryptically
spliced isoform and the number of reads that do not support the use
of the cryptic splice site (i.e. non-cryptic corroborating) in the same
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genomic region of a sample. Cryptic corroborating reads are those
which occur within the expected region where cryptic splicing
occurs (i.e. spliced-in regions). This region is bounded by the variant splice site location and the adjacent (direction dependent) splice
junction (Equation 1(a)). Non-cryptic corroborating reads, which
we also term “anti-cryptic” reads, are those that do not lie within
this region, but would still be retained within the portion that would
be excised, had cryptic splicing occurred (Equation 1(b)). To identify instances of exon skipping, Veridical only employs junctionspanning reads. A read is considered to corroborate exon skipping
if the connecting read segments are split such that it connects two
exon boundaries, skipping an exon in between (Equation 1(c)). A
read is considered to corroborate intron inclusion when the read
is continuous and either overlaps with the intron-exon boundary
(and is then said to be junction-spanning) or if the read is within
an intron (and is then said to be based upon read-abundance). We
only consider an intron inclusion read to be junction spanning if it
spans the relevant splice junction, A. Equation 1(d) formalizes this
concept. We occasionally use the term “total intron inclusion” to
denote that any such count of intron inclusion reads includes both
those containing and not containing the mutation itself. Graphical
examples of some of these validation events, with a defined variant
location, are provided in Figure 2.
We proceed to formalize the above descriptions as follows. A given
read is denoted by r, with start and end coordinates (rs, re), if the
read is continuous, or otherwise, with start and end coordinate pairs,
(rs1, re1) and (rs2, re2) as diagrammed within Figure 2. Let ℓ be the
length of the read. The set ζ denotes the totality of validating reads.
The criterion for r ∈ ζ is detailed below. It is important to note that
validating reads are necessary but not sufficient to validate a variant. Sufficiency is achieved only if the number of validating reads is
statistically significant relative to those present in control samples.
ζ itself is partitioned into three sets: ζc, ζe, and ζi for evidence of
cryptic splicing, exon skipping, and intron inclusion, respectively.
We allow partitions to be empty. Let JC denote the adjacent splice
junction, and let B denote the downstream natural site, as defined
by Figure 2 and Table 1. Without loss of generality, we consider
only the red (i.e. direction is right) set of labels within Figure 1(B),
as further typified by Figure 2. Then the (splice consequence) partitions of ζ are given by:

( )

yel-

low

( )

purple
green

( )

r ∈ ζc ⇔ variant is cryptic ∧ (rs2 – re1 = B

(1a)
Figure 2. Illustrative examples of aberrant splicing detection. Grey
– JC ∨ (rs > JC ∧ re < A))				  lines denote reads, wherein thick lines denote a read mapping to

genomic sequence and thin lines represent connecting segments
of reads split across spliced-in regions (i.e. exons or included
introns). Dotted blue rectangles denote portions of genes which
(1b)
⇒ r ∈ anti-cryptic				  are spliced out in a mutant transcript, but are otherwise present
in a normal transcript. Mutant reads are purple if they are junctionr ∈ ζe ⇔ (re1= D ∧ rs2 = E)				 
(1c)
spanning and green if they are read-abundance based. Start and
end coordinates of reads with two portions are denoted by (rs , re )
1
1
and (rs , re ), while coordinates of those with only a single portion
r ∈ ζi ⇔ (A∈ [rs, re]) ∨ ((A ∉ [rs, re])
2
2
are denoted by (rs, re). Refer to the caption of Figure 1 for additional
(1d)
∧ rs > A – ℓ ∧ re < B ∧ ¬ (A ∈ [rs, re]))		 
graphical element descriptions.

r ∉ ζc ∧ variant is cryptic ∧ ¬ ( rs2 – re1 = B – JC)
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All increment operations
increment the field
pertaining to either an
experimental or control
sample, depending
upon where the read
originated.

Get next read’s
details . Retrieved
reads are at least
partially between
D and E

Checked all transcripts
Increment
junction
spanning
cryptic
splicing count

Check if there are
more transcripts for the
variant’s gene

Unchecked transcripts exist
Check
read with
respect to
next
transcript

Compute
expected
alignment gap
E = |C - B |

Cryptic

Equal

Splice site
type

Compute
observed
alignment
gap O from
read

Natural
Compute
observed
alignment gap
O from read

Compute
expected
alignment gap
E = |E - D |

Not equal

Compare
E and O

Not equal

Read is between ‘B’ and ‘C’

Check if read is within the expected
region for cryptic splicing

Compare
E and O

Not equal
Check for gaps in read
alignment

Does not have alignment gaps

Read is between ‘A’ and ‘C’

Equal
Increment
junction
spanning
exon
skipping
count

Read is between ‘A’ and ‘B’ (or overlaps either )

Increment
read
abundance
cryptic
splicing
contradicting
count

Increment junction
spanning intron
inclusion count

Check if any part of the read is
intronic

Check if the read
overlaps the intron-exon
boundary

Increment
read
abundance
cryptic
splicing
corroborating
count

Overlaps

No overlap

Increment read
abundance intron
inclusion count

Figure 3. The algorithm employed by Veridical to validate variants. Refer to Table 1 for definitions concerning direction and Figure 1 for
variable depictions. B is defined as follows: B (B site left (←) of A ⇒ B := D. B site right (→) of A ⇒ B := E.
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We separately partition ζ by its evidence type, the set of junctionspanning reads, δ and read-abundance reads, α:

The program outputs two tables, along with summaries thereof.
The first table lists all validated read counts across all categories
for experimental samples, while the second table does the same for
r ∈ δ ⇔ (A ∈ [rs, re]) ∨ (r ∈ ζc ∧ rs2 – re1 = B – JC)	 (1e)
the control samples. P-values are shown in parentheses within the
experimental table, which refer to the column-dependent (i.e. the
r ∈ α ⇔ r ∉ δ					 
(1f)
read type is given in the column header) p-value for that read type
with respect to that same read type in control samples. The program
Once all validating reads are tallied for both the experimental and
produces three files: a log file containing all details regarding valicontrol samples, a p-value is computed. This is determined by comdated variants, an output file with the programs progress reports and
puting a z-score upon Yeo-Johnson (YJ)16 transformed data. This
summaries, and a filtered validated variant file. The filtered file contransformation, shown in Equation 2, ensures that the data is suftains all validated variants of statistical significance (set as p < 0.05,
ficiently normally distributed to be amenable to parametric testing.
by default), defined as variants with one or more validating reads
achieving statistical significance in a strongly corroborating read
 ( x + 1)λ − 1
type. These categories are limited to all junction-spanning based
≥
∧
≠
if
0
0
λ
x

splicing consequences and read-abundance total intron inclusion.
λ

For example, a cryptic variant for which p = 0.04 in the junctionif x ≥ 0 ∧ λ = 0
 log( x + 1)
spanning cryptic column would meet this criteria, assuming the
(2)
ψ (x , λ ) = 
2−λ
default significance threshold.
 (− x + 1) − 1

−

2−λ

log(
x + 1)
−
−


if x < 0 ∧ λ ≠ 2

if x < 0 ∧ λ = 2

The transform is similar to the Box-Cox power transformation, but
obviates the requirement of inputting strictly positive values and
has more desirable statistical properties. Furthermore, this transformation allowed us to avoid the use of non-parametric testing, which
has its own pitfalls regarding assumptions of the underlying data
1
distribution17. We selected λ = –2, because Veridical’s untransformed
output is skewed left, due to their being, in general, less validating
reads in control samples and the fact that there are, by design, vastly
more control samples than experimental samples. We found that
this value for λ generally made the distribution much more normal. A comparison of the distributions of untransformed and transformed data is provided in Figure S1. We were not concerned about
small departures from normality as a z-test with a large number of
samples is robust to such deviations18.
Thus, we can compute the p-value of the pairwise unions of the two
sets of partitions of ζ, except the irrelevant ζe ∪ α = Ø. We only
provide p-values for these pairwise unions and do not attempt to
provide p-values for the partitions for the different consequences of
the mutations on splicing. While such values would be useful, we
do not currently have a robust means to compute them. Our previous work provides guidance on interpretation of splicing mutation
outcomes3–5,10. Thus for ζx ∈ {ζc, ζe, ζi}, let ΦZ (z) represent the
cumulative distribution function of the one-sided (right-tailed —
i.e. P[X > x]) standard normal distribution. Let N represent the total
number of samples and let V represent the set of all ζx validations,
across all samples. Then:
N

µ=
z=

∑V
j =1

j

N
|ζ x | −µ
σ

σ =

1
N

N

∑ (V
j =1

j

−V )

p = Φ (ψ ( z , 12 ))

2

The p-values given by Veridical are more robust when the program
is provided with a large number of samples. The minimum sample
size is dependent upon the desired power, α value, and the effect
size (ES). The minimum samples size could be computed as follows: N =  σESz . For α = 0.05 and β = 0.2 (for a power of 0.8): z =
. Ideally, Veridical
2.4865 for the one-tailed test. Then, N =  σ 2.4865

ES
could be run with a trial number of samples.
2 2
2

2

2

2

Then, one would compute effect sizes from Veridical’s output. The
standard deviation in the above formula could also be estimated
from one’s data, although it should be transformed using YeoJohnson (such as via an appropriate R package) before computing
this estimation.
We elected to use RefSeq19 genes for the exome annotation, as
opposed to, the more permissive exome annotation sets, UCSC
Known Genes20 or Ensembl21. The large number of transcript variants
within Ensembl, in particular, caused many spurious intron inclusion validation events. This occurred because reads were found to be
intronic in many cases, when in actuality they were exonic with
respect to the more common transcript variant. In addition, the inclusion of the large number of rare transcripts in Ensembl significantly
increased program run-time and made validation events much more
challenging to interpret unequivocally. The use of RefSeq, which
is a conservative annotation of the human exome, resolves these
issues. It is possible that some subset of unknown or Ensemble
annotated intronic transcripts could be sufficiently prevalent to merit
inclusion in our analysis. We do not attempt to perform the difficult
task of deciding which of these transcripts would be worth using.
Indeed, the task of confirming and annotating of such transcripts is
already done by the more conservative annotation we employ.
We also provide an R program22 which produces publication quality
histograms displaying embedded Q-Q plots and p-values, to evaluate for normality of the read distribution and statistical significance,
respectively. The R program performs the YJ transformation as
implemented in the car package23. The histograms generated by the
program use the Freedman-Draconis24 rule for break determination,
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and the Q-Q plots use algorithm Type 8 for their quantile function,
as recommended by Hyndman and Fan25. This program is embedded within a Perl script, for better integration into our workflow.
Lastly, a Perl program was implemented to automatically retrieve
and correctly format an exome annotation file from the UCSC
database20 for use in Veridical. All data use hg19/GRCh37, however
when new versions of the genome become available, this program
can be used to update the annotation file.

within the supplementary methods of the TCGA paper26. Accordingly,
the following examples demonstrate the utility of Veridical to identify potentially pathogenic mutations from a much larger subset of
predicted variants.
Input, output, and explanatory files for Veridical
5 Data Files
http://dx.doi.org/10.6084/m9.figshare.894971

Results
Veridical validates predicted mRNA splicing mutations using highthroughput RNA sequencing data. We demonstrate how Veridical
and its associated R program are used to validate predicted splicing
mutations in somatic breast cancer. Each example depicts a particular variant-induced splicing consequence, analyzed by Veridical,
with its corresponding significance level. The relevant primary
RNA-Seq data are displayed in IGV, along with histograms and
Q-Q plots showing the read distributions for each example. The
source data are obtained from controlled-access breast carcinoma
data from The Cancer Genome Atlas (TCGA)26. Tumour-normal
matched DNA sequencing data from the TCGA consortium was used
to predict a set of splicing mutations, and a subset of corresponding
RNA sequencing data was analyzed to confirm these predictions
with Veridical. Overall, 442 tumour samples and 106 normal
samples were analyzed. Briefly, all variants used as examples in
this manuscript came from running the matched TCGA exome files
(to which the RNA-Seq data corresponds) through SomaticSniper27
and Strelka28 to call somatic mutations, followed by the Shannon
Human Splicing Pipeline10 to find splicing mutations, which served
as the input to Veridical. Details of the RNA-Seq data can be found
(A)

Leaky Mutations
Mutations that reduce, but not abolish, the spliceosome’s ability to
recognize the intron/exon boundary are termed leaky3. This can lead
to the mis-splicing (intron inclusion and/or exon skipping) of many
but not all transcripts. An example, provided in Figure 4, displays
a predicted leaky mutation (chr5:162905690G>T) in the HMMR
gene in which both junction-spanning exon skipping (p < 0.01)
and read-abundance-based intron inclusion (p = 0.04) are observed.
We predict this mutation to be leaky because its final Ri exceeds
1.6 bits — the minimal individual information required to recognize a splice site and produce correctly spliced mRNA4. Indeed,
the natural site, while weakened by 2.16 bits, remains strong —
10.67 bits. This prediction is validated by the variant-containing
sample’s RNA-Seq data (Figure 4), in which both exon skipping
(5 reads) and intron inclusion (14 reads, 12 of which are shown,
versus an average of 4.051 such reads per control sample) are
observed, along with 70 reads portraying wild-type splicing. Only
a single normally spliced read contains the G→T mutation. These
results are consistent with an imbalance of expression of the two
(B)

Figure 4. IGV images depicting a predicted leaky mutation (chr5:162905690G>T) within the natural acceptor site of exon 12 (162905689–
162905806) of HMMR. This gene has four transcript variants and the given exon number pertains to isoforms a and b (reference sequences
NM_001142556 and NM_012484). RNA-Seq reads are shown in the centre panel. The bottom blue track depicts RefSeq genes, wherein
each blue rectangle denotes an exon and blue connecting lines denote introns. In the middle panel, each rectangle (grey by default) denotes
an aligned read, while thin lines are segments of reads split across exons. Red and blue coloured rectangles in the middle panel denote
aligned reads of inserts that are larger or smaller than expected, respectively. Reads are highlighted by their splicing consequence, as
follows: cryptic splicing (green), exon skipping (purple), junction-spanning intron inclusion (dark green), and read-abundance intron inclusion
(cyan). (A) depicts a genomic region of chromosome 5: 162902054–162909787. The variant occurs in the middle exon. Intron inclusion can
be seen in this image, represented by the reads between the first and middle exon (since the direction is left, as described within Table 1).
These 14 reads are read-abundance-based, since they do not span the intron-exon junction. (B) depicts a closer view of the region shown in
(A) — 162905660–162905719. The dotted vertical black lines are centred upon the first base of the variant-containing exon. The thin lines in
the middle panel that span the entire exon fragment are evidence of exon skipping. These 5 reads are split across the exon before and after
the variant-containing exon, as seen in (A).
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Figure 5. Histogram of read-abundance-based intron inclusion with embedded Q-Q plots of the predicted leaky mutation (chr5:162905690G>T)
within HMMR, as shown in Figure 4. The arrowhead denotes the number of reads (14 in this case) in the variant-containing file, which is more
than observed in the control samples (p = 0.04).

alleles, as expected for a leaky variant. Figure 5 shows that for the
distribution of read-abundance-based intron inclusion is marginally
statistically significant (p = 0.04).

Inactivating Mutations
Variants that inactivate splice sites have negative final Ri values3
with only rare exceptions4, indicating that splice site recognition
is essentially abolished in these cases. We present the analysis of
two inactivating mutations within the PTEN and TMTC2 genes
from different tumour exomes, namely: chr10:89711873A>G and
chr12:83359523G>A, respectively. The PTEN variant displays
junction-spanning exon skipping events (p < 0.01), while the TMTC2
gene portrays both junction-spanning and read-abundance-based
intron inclusion (both splicing consequences with p < 0.01). In
addition, all intron inclusion reads in the experimental sample contain the mutation itself, while only one such read exists across all
control samples analyzed (p < 0.01). The PTEN variant contains
numerous exon skipping reads (32 versus an average of 2.466 such
reads per control sample). The TMTC2 variant contains many junctionspanning intron inclusion reads with the G→A mutation (all of its
junction-spanning intron inclusion reads: 22 versus an average of
0.002 such reads per control sample). IGV screenshots for these
variants are provided within Figure 6. This figure also shows an
example of junction-spanning cryptic splice site activated by the

mutation (chr1:985377C>T) within the AGRN gene. The concordance
between the splicing outcomes generated by these mutations and
the Veridical results indicates that the proposed method detects both
mutations that inactivate splice sites and cryptic splice site activation.

Cryptic Mutations
Recurrent genetic mutations in some oncogenes have been reported
among tumours within the same, or different, tissues of origin.
Common recurrent mutations present in multiple abnormal samples are recognized by Veridical. This avoids including a variantcontaining sample among the control group, and outputs the results
of all of the variant-containing samples. A relevant example is shown
in Figure 7. The mutation (chr1:46726876G>T) causes activation
of a cryptic splice site within RAD54L in multiple tumours. Upon
computation of the p-values for each of the variant-containing
tumours, relative to all non-variant containing tumours and normal controls, not all variant-containing tumours displayed splicing
abnormalities at statistically significant levels. Of the six variantcontaining tumours, two had significant levels of junction-spanning
intron inclusion, and one showed statistically significant readabundance-based intron inclusion. Details for all of the aforementioned variants, including a summary of read counts pertaining to
each relevant splicing consequence, for experimental versus control
samples, are provided in Table 2.
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(A)

(B)

(C)

(D)

Figure 6. (A) depicts an inactivating mutation (chr10:89711873A>G) within the natural acceptor site of exon 6 (89711874–89712016)
of PTEN. The dotted vertical black line denotes the location of the relevant splice site. The region displayed is 89711004–89712744 on
chromosome 10. Many of the 32 exon skipping reads are evident, typified by the thin lines in the middle panel that span the entire exon.
There is also a substantial amount of read-abundance-based intron inclusion, shown by the reads to the left of the dotted vertical line. Exon
skipping was statistically significant (p < 0.01), while read-abundance-based intron inclusion was not (p = 0.53). Panels (B) and (C) depict
an inactivating mutation (chr12:83359523G>A) within the natural donor site of exon 6 (83359338–83359523) of TMTC2. (B) depicts a closer
view (83359501–83359544) of the region shown in (C) and only shows exon 6. Some of the 22 junction-spanning intron inclusion reads can
be seen. In this case, all of these reads contain the mutation, shown by the green adenine base in each read, between the two vertical dotted
lines. (C) depicts a genomic region of chromosome 12: 83359221–83360885, TMTC2 exons 6–7. The variant occurs in the left exon. 65 readabundance-based intron inclusion can be seen in this image, represented by the reads between the two exons. Panel (D) depicts a mutation
(chr1:985377C>T) causing a cryptic donor to be activated within exon 27 (the second from left, 985282–985417) of AGRN. The region
displayed is 984876–985876 on chromosome 1 (exons 26–29 are visible). Some of the 34 cryptic (junction-spanning) reads are portrayed.
The dotted black vertical line denotes the cryptic splice site, at which cryptic reads end. The read-abundance-based intron inclusion, of
which two reads are visible, was not statistically significant (p = 0.68). Refer to the caption of Figure 4 for IGV graphical element descriptions.

Performance
The performance of the software is affected by the number of predicted splicing mutations, the number of abnormal samples containing mutations and control samples and the corresponding RNA-Seq
data for each type of sample. Veridical has the ability to analyze

approximately 3000 variants in approximately 4 hours, assuming an
input of 100 BAM files of RNA-Seq data. The relationship between
time and numbers of BAM files and variants are plotted in Figure 8
for a 2.27 GHz processor. Veridical uses memory in linear proportion to the number and size of the input BAM files. In our tests,
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Figure 7. IGV images and their corresponding histograms with embedded Q-Q plots depicting all six variant-containing files with a mutation
(chr1:46726876G>T) which, in some cases, causes a cryptic donor to be activated within the intron between exons 7 and 8 of RAD54L. This
results in the extension of the downstream natural donor (the 5′ end of exon 8). This gene has two transcript variants and the given exon
numbers pertain to isoform a (reference sequence NM_003579). Only samples IV and V have statistically significant intron inclusion relative
to controls. read-abundance-based intron inclusion can be seen in (A), between the two exons. The region displayed is on chromosome 1:
46726639–46726976. (B) depicts the corresponding histogram for the 15 read-abundance-based intron inclusion reads (p = 0.05) that are
present in sample IV. The intron-exon boundary on the right is the downstream natural donor. (C) typifies some of the 13 junction-spanning
intron inclusion reads that are a direct result of the intronic cryptic site’s activation. In these instances, reads extending past the intron-exon
boundary are being spliced at the cryptic site, instead of the natural donor. In particular, samples IV and V both have a statistically significant
numbers of such reads, 7 (p = 0.01) and 5 (p = 0.04), respectively. This is further typified by the corresponding histogram in (D). (C) focuses
upon exon 8 from (A) and displays the genomic positions 46726908–46726957. Refer to the caption of Figure 4 for IGV graphical element
descriptions. In the histograms, arrowheads denote numbers of reads in the variant-containing files. The bottom of the plots provide p-values
for each respective arrowhead. Statistically significant p-values and their corresponding arrowheads are denoted in red.
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Table 2. Examples of variants validated by Veridical and their selected read types. Header abbreviations Chr, Cv, Cs, #, SC, and ET, denote
chromosome, variant coordinate, splice site coordinate, sample number (where applicable), splicing consequence, and evidence type,
respectively. Headers containing R with some subscript denote numbers of validated reads for the specified variant’s splicing consequence(s)
and evidence type(s). RE denotes reads within variant-containing tumour samples. RT and RN denote control samples, for tumours and normal
cells, respectively. Rμ is the per sample mean of RT and RN. Splicing consequences: CS denotes cryptic splicing, ES denotes exon skipping, and
II denotes intron inclusion. Evidence types: JS denotes junction-spanning and RA denotes read-abundance.
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Figure 8. Profiling data for Veridical runtime. Tests were conducted upon an Intel Xeon @ 2.27 GHz. Visualizations were generated with R22
using Lattice30 and Effects31. A surface plot of time vs. numbers of BAM files and variants is provided in (A). Effect plots are given in (B) and
demonstrate the effects of the numbers of BAM files and variants upon runtime. The effect plots were generated using a linear regression
model (R 2 = 0.7525).
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using RNA-Seq BAM files with an average size of approximately
6 GB, Veridical used approximately 0.7 GB for ten files to 1 GB
for 100 files.

allows for manual inspection to discover samples that contained the
alternative splicing pattern, and consequently, permits the identification of DNA mutations in the same location which went undetected during genome sequencing.

Discussion
We have implemented Veridical, a software program that automates
confirmation of mRNA splicing mutations by comparing sequence
read-mapped expression data from samples containing variants
that are predicted to cause defective splicing with control samples lacking these mutations. The program objectively evaluates
each mutation with statistical tests that determine the likelihood
of and exclude normal splicing. To our knowledge, no other software currently validates splicing mutations with RNA-Seq data on
a genome-wide scale, although many applications can accurately
detect conventional alternative splice isoforms (i.e.29). Veridical is
intended for use with large data sets derived from many samples,
each containing several hundred variants that have been previously
prioritized as likely splicing mutations, regardless of how the candidate mutations are selected. It is not practical to analyze all variants
present in an exome or genome, rather only a filtered subset, due
to the extensive computations required for statistical validation. As
such, Veridical is a key component of an end-to-end, hypothesisbased, splicing mutation analysis framework that also includes the
Shannon splicing mutation pipeline10 and the Automated Splice Site
Analysis and Exon Definition server5. There is a trade-off between
lengthy run-times and statistical robustness of Veridical, especially
when there are either a large number of variants or a large number
of RNA-Seq files. As with most statistical methods, those employed
here are not amenable to small sample sets, but become quite powerful when a large number of controls are employed. In order to
ensure that mutations can be validated, we recommend an excess
of control transcriptome data relative to those from samples containing mutations (> 5 : 1), guided by the power analysis described
in Methods. We do not recommend the use of a single nor a few
control samples to corroborate a putative mutation. Not surprisingly, we have found that junction-spanning reads have the greatest
value for corroborating cryptic splicing and exon skipping. Even a
single such read is almost always sufficient to merit the validation
of a variant, provided that sufficient control samples are used. For
intron inclusion, both junction-spanning and read-abundance-based
reads are useful and a variant can readily be validated with either,
provided that the variant-containing experimental sample(s) show
a statistically significant increase in the presence of either form of
intron inclusion corroborating reads.
Veridical is able to automatically process variants from multiple
different experimental samples, and can group the variant information if any given mutation is present in more than one sample. The
use of a large sample size allows for robust statistical analyses to be
performed, which aid significantly in the interpretation of results.
The main utility of Veridical is to filter through large data sets of
predicted splicing mutations to prioritize the variants. This helps to
predict which variants will have a deleterious effect upon the protein product. Veridical is able to avoid reporting splicing changes
that are naturally occurring through checking all variant-containing
and non-containing control samples for the predicted splicing consequence. In addition, running multiple tumour samples at once

The statistical power of Veridical is dependent upon the quality of
the RNA-Seq data used to validate putative variants. In particular, a
lack of sufficient coverage at a particular locus will cause Veridical
to be unable to report any significant results. A coverage of at least
20 reads should be sufficient. This estimate is based upon alternative
splicing analyses in which this threshold was found to imply concordance with microarray and RT-PCR measurements32–35. There
are many potential legitimate reasons why a mutation may not be
validated: (a) A lack of gene expression in the variant containing
tumour sample, (b) nonsense-mediated decay may result in a loss
of expression of the entire transcript, (c) the gene itself may have
multiple paralogs and reads may not be unambiguously mapped,
(d) other non-splicing mutations could account for a loss of expression, and (e) confounding natural alternative splicing isoforms may
result in a loss of statistical significance during read mapping of the
control samples. The prevalence of loci with insufficient data is
dependent upon the coverage of the sequencing technology used. As
sequencing technologies improve, the proportion of validated mutations is expected to increase. Such an increase would mirror that
observed for the prevalence of alternative splicing events36. In addition, mutated splicing factors can disrupt splicing fidelity and exon
definition37. This effect could decrease Veridical’s ability to validate
splicing mutations affected by a disruption of the definition of the
pertinent exon. Veridical does not currently form any equivalence
between distinct variants affecting the same splice site. Such variants will be analyzed independently. Veridical is intended to be used
with RNA-Seq data that not only corresponds to matched DNA-Seq
data, but also only for sets of samples with comparable sequencing
protocols, since the non-normalized comparisons performed rely
upon the evening out of batch effects, due to a substantial number
of control samples. It is important to note that acceptance of the
null hypothesis, due to an absence of evidence required to disprove
it, does not imply that the underlying prediction of a mutation at a
particular locus is incorrect, but merely that the current empirical
methods employed were insufficient to corroborate it.
“Validate,” in the present context, refers to the condition where
sufficient statistical evidence has been marshaled in support of a
variant. However, the threshold for significance can vary so these
analyses can also be thought of as strongly corroborating variants.
Recent studies in Bayesian statistics have suggested that a p-value
threshold of 0.05 does not correspond to strong support of the alternative hypothesis. Accordingly, Johnson38 recommends the use of
tests at the 0.005 or 0.001 level of significance.
We consider alternative splicing to be a different problem. Veridical
does not aim to identify putatively pathogenic variants, but rather,
to confirm existing in silico predictions thereof. We do infer exon
skipping events (i.e. alternative splicing) de novo, but only to catalog dysregulated splicing “phenotypes” due to genomic sequence
variants. This is not the first study to use a large control dataset.
Indeed the Variant Annotation, Analysis & Search Tool (VAAST)39
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does this to search for disease-causing (non-splicing) variants and
the Multivariate Analysis of Transcript Splicing (MATS)29 tool
(among others) can be used for the discovery of alternative splicing
events. However, in our case, in most instances the distribution of
reads in a single sample is compared to the distributions of reads
in the control set, as opposed to a likelihood framework-based
approach. We are suggesting that our approach be coupled to existing approaches to act as an a posteriori, hypothesis-driven, check
on the veridicality of specific variants.
While there is considerable prior evidence for splicing mutations
that alter natural and cryptic splice site recognition, we were somewhat surprised at the apparent high frequency of statistically significant intron inclusion revealed by Veridical. In fact, evidence
indicates that a significant portion of the genome is transcribed36,
and it is estimated that 95% of known genes are alternatively
spliced32. Defective mRNA splicing can lead to multiple alternative
transcripts including those with retained introns, cassette exons,
alternate promoters/terminators, extended or truncated exons, and
reduced exons40. In breast cancer, exon skipping and intron retention were observed to be the most common form of alternative
splicing in triple negative, non-triple negative, and HER2 positive
breast cancer41. In normal tissue, intron retention and exon skipping
has been predicted to affect 2572 exons in 2127 genes and 50 633
exons in 12 797 genes, respectively42. In addition, previous studies suggest that the order of intron removal can influence the final
mRNA transcript composition of exons and introns43. Intron inclusion observed in normal tissue may result from those introns that
are removed from the transcript at the end of mRNA splicing. Given
that these splicing events are relatively common in normal tissues,
it becomes all the more important to distinguish expression patterns
that are clearly due to the effects of splicing mutations — one of the
guiding principles of the Veridical method.
Veridical is an important analytical resource for unsupervised, thorough validation of splicing mutations through the use of companion RNA-Seq data from the same samples. The approach will be
broadly applicable for many types of genetic abnormalities, and
should reveal numerous, previously unrecognized, mRNA splicing
mutations in exome and complete genome sequences.

Data availability
figshare: Input, output, and explanatory files for Veridical, http://
dx.doi.org/10.6084/m9.figshare.89497144.
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Supplementary materials
Veridical variant input format
This input format most easily accepts formatted output from the
Shannon Pipeline. In particular, all variants of interest should be
concatenated into a single file. Once a, tab-delimited, concatenated
file has been generated, it can easily be formatted correctly by using
FilterShannonPipelineResults.pl. All file headers must
precisely match their outlined schema. One can also manually ensure
the following: the header line has no quotation marks or special
characters, empty columns have been replaced by a period (.) and
each variant line contains only a single gene (comma-delimited
gene lists must be split such that there is only one gene per line).
If one wishes Veridical to consider variants pertaining to more than
one experimental sample, a comma-delimited list of experimental
samples, in the form of BAM file names, must be provided as the
key column. The key column must always contain at least one file
name that is present as the base name of one of the files listed in the
BAM file list that must be passed to Veridical.
Alternatively, one can prepare the input format as follows. The header
must contain at least the following, case-insensitive, values to which
the file’s columns must adhere to: chromosome, splice&coordinate,
strand, type, gene, location, location_type, heterozygosity, variant,
input, key. The column headers need only contain the given text
(i.e. a column labeled gene_name would be sufficient to satisfy
the above requirement for a “gene” column). Column headers with
ampersands (&) denote that all words joined by this symbol must
be present for that column (i.e. Splice_site_coordinate
satisfies the “splice&coordinate” requirement). The order of the
columns is immaterial. The input column can contain any identifier for the variant and need not be unique. The location column
specifies if the site is natural or cryptic. For Veridical, all that matters is that cryptic variants contain the word “cryptic” as part
of their value in this column and that non-cryptic variants do not.
The location_type column is only used for cryptic variants
and specifies if the variant is intronic or exonic. It is not currently
used by the program. This column must be present but can always
be set to null (i.e).
A few rows from a sample variant file is provided below (text
wrapped for readability):
Chromosome   Splice_site_coordinate   Strand
Ri-initial Ri-final ∆Ri Type Gene_Name Location
Location_Type Loc._Rel._to_exon
Dist._from_nearest_nat._site
Loc._of_nearest_nat._site	 Ri_of_nearest_nat
Cryptic_Ri_rel._nat. rsID Average_heterozygosity
Variant_coordinate   Input_variant	  Input_ID
RNASeqDirectory_ID RNA_Seq_BAM_ID_KEY
chr10 89711874 + 12.09 -2.62 -14.71 ACCEPTOR PTEN
NATURALSITE . . . . . . . . 89711873 A/G ID1 dir
file
chr10 89712017 + 5.18 -1.85 -7.03   DONOR   PTEN
NATURALSITE . . . . . . . . 89712018 T/C ID1 dir
file
chrX 9621719 + -4.78 2.25 7.03   DONOR   TBL1X
CRYPTICSITE EXONIC . 11 9621730   2.24   GREATER .
. 9621720 C/T ID1 dir file

Veridical exome annotation input format
This input format can be generated via ConvertToExomeAnnotation.
pl. The file must be tab-delimited, excepting its header, which must
be comma-delimited. It must have the following, case-insensitive,
header columns, to which its data must adhere: transcript, chromosome, exon chr start, exon chr end, exon rank, gene. The column
headers need only contain the given text (i.e. a column labeled
gene_name would be sufficient to satisfy the above requirement
for a “gene” column). The order of the columns is immaterial.
A few rows from a sample exome annotation file is provided below
(text wrapped for readability):
Transcript ID,ID,ID,Chromosome Name,Strand,
Exon Chr Start,Exon Chr End,
Exon Rank in Transcript,Transcript Start,
Transcript End, Associated Gene Name
NM_213590 NM_213590
NM_213590 chr13 + 50571142
50571899 1 50571142
50592603 TRIM13
NM_213590 NM_213590
NM_213590 chr13 + 50586070
50592603 2 50571142
50592603 TRIM13
NM_198318 NM_198318
NM_198318 chr19 + 50180408
50180573 1 50180408
50191707 PRMT1

Veridical output
If a variant contains any validating reads, Veridical outputs the variant in question, along with some summary information and a table
specifying the numbers of each validating read type detected for
both the experimental and control samples. Within the output of
Veridical, the phrase: “Validated (x) variant n times” means that the
variant was validated mainly for splicing consequence x and has n
validating reads. The variant will only appear within the *.filtered
output file if the p-value for either junction-spanning or readabundance-based reads for splicing consequence x was statistically
significant (defined, by default, as: p < 0.05). After the variant
being validated is provided, along with its primary predicted splicing consequence, the output is divided into two sections with identical contents: one for the experimental sample(s) and another for
control samples. The summary enumerates the number of reads of
each splicing consequence, partitioned by evidence type (junctionspanning or read-abundance-based), and by sample type (tumour
or normal for control samples, and only tumour for experimental
samples). A table describing the number of each read type for every
file follows this summary. An example of this output, for the variant
within RAD54L, as shown by Figure 7 and the last portion of Table 2,
is provided. While Veridical outputs this as plain text, with the table
in a tab-delimited format, we provide this output as an Excel document with descriptions of the meaning of each table heading, to clarify the presentation of the data. All input and output files for the five
variants presented are provided. VeridicalOutExample.xls
contains the output for the variant within RAD54L, along with
descriptions of the terms used and the output format. all.vin
contains the input variant file. allTumoursBAMFileList.txt
and allNormalsBAMFileList.txt are the BAM file lists
for tumour and normal samples, respectively. all.vout contains the Veridical output. The exome file can be retrieved using
ConvertToExomeAnnotation.pl, available with the other
programs at: www.veridical.org. The BAM file lists contain the
TCGA file UUID, followed by a slash, followed by the file name.
The RNA-Seq data itself can be downloaded from TCGA at: https://
tcga-data.nci.nih.gov/tcga/.
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Figure S1. Histogram and embedded Q-Q plots portraying the difference between untransformed and Yeo-Johnson (YJ) transformed data.
The plots depict intron inclusion for the inactivating mutation (chr12:83359523G>A) within TMTC2, as shown in Figures 6(B) and 6(C). The
arrowheads denote the number of reads in the variant-containing file, which is, in all cases, more than observed in the control samples
(p < 0.01). The figure legend for all panels is provided in (G), which shows that blue and red plot elements correspond to untransformed
data, while yellow and purple correspond to YJ transformed elements. Dotted lines in the Q-Q plots are lines passing through the first
and third quantiles for a normal reference distribution. (A), (C), and (E) show junction-spanning based reads, while (B), (D), and (F) show
read-abundance-based reads. (A)–(B) depict tumour sample distributions, (B)–(C) depict normal sample distributions, and (E)–(F) depict
combined tumour and normal sample distributions. This figure is demonstrative of the general trend we have observed. Only data from normal
samples resemble a Gaussian distribution and the YJ transformation greatly improves the Gaussian nature of all distributions.
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Referee Responses for Version 1
Peter Robinson
Institute for Medical Genetics, Universitätsklinikum Charité, Berlin, Germany
Approved: 18 March 2014
Referee Report: 18 March 2014
This paper from the Rogan group presents a methodology for validation of DNA sequencing variants that
alter mRNA splicing. While variants of the most conserved splice site nucleotides at the intron-exon
boundary can be predicted to cause splice defects with high reliability, it remains difficult to predict
whether variants deeper in the intron or those that potentially affect exonic splicing enhancers actually
cause splice defects. RNA-seq data, when coupled with variant data, potentially provide a means of
correlating variation data with observations of (mis-)splicing patterns.
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correlating variation data with observations of (mis-)splicing patterns.
The program fulfils an important need in the community, the results appear promising and will be of
special interest to groups performing RNA-seq analysis in medical settings. I have only some minor
suggestions that the authors may like to consider.

Suggestions:
1. The explanation of the methodology is relatively difficult to follow, and I wonder if it might not be
better to simplify Figures 1 and 2 for didactic sake. For instance, in Figure 1A, it is unclear where
the location of variant C is. Does the curved line mean that it could be anywhere in the middle
exon? Also, I assume that exons are being shown in blue and reads shown in gray?
Also, the legend text is overly complicated: D > E swap D and E. While aficionados of first order
logic will follow without problems, I would suggest that it would be better for didactic purposes to
delete this and to implicitly assume that D<E for the sake of this figure. Figure 1B is confusing at
this point in the manuscript because the motivation for switching the variable A,B, D, and E is not
yet clear. On the other hand, panel C and panel D are trivial and do not add anything. I would
suggest using Figure 1 to provide one concrete example one a simple level, and stating in the text
that the variables are to be switched if the candidate mutation is located on the other side of the
exon.
Also, the explanations of the method that are couched in first order logic-like notation are difficult to
follow, because it is not stated whether the variant C can precede the start of the read (in which
case C-S would be negative). The subscripts for r in turn have the subscript s1 but the variable S in
the formula does not.
Although in the end, I think I follow the overall method, the reader is forced to make arbitrary
assumptions in order to interpret the formulae being used to explain the method. A similar
comment pertains to the flow chart in Figure 2.
Therefore, I would suggest the authors take some pains to improve the clarity of the explanation of
the method. I would suggest that they show one of two concrete examples and provide English
language specifications of the FOL-like formulae that describe the partitioning of reads.
2. I am a little unclear on the use of control samples vs experimental samples. Assuming the
experimental samples come from different individuals, what is the reason to assume that they will
have the same distribution of splice mutations? And given that one finds dozens of splice variants
in normal individuals, what exactly is meant by a control sample? Will control samples not also
have lots of splice mutations? How does the method deal with this? And if we are dealing with
cancer samples, why not user a paired control to detect cancer-specific mutations? In light of this,
the statement "Maximizing the set of control samples, while computationally more expensive,
increases the statistical robustness of the results obtained.", does not appear to be supported by
evidence presented in the manuscript.
3. It would be interesting to see a comparison of the distribution of Ri values and results of Veridical
analysis?

4. How does Veridical decide which sequence variant is causative if there are multiple variations
F1000Research
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4. How does Veridical decide which sequence variant is causative if there are multiple variations
located in the vicinity of a given mis-spliced exon?
5. The mutation nomenclature chr1:985377 C>T should not have a space between the position and
the nucleotides.
6. It is unclear to me why a linear regression model was used to show the performance of the method.
The authors could provide timings from real runs.
7. It would be interesting to see a plot on the relationship of the p-values called by Veridical and the
sequencing depth covered. The authors state "In particular, a lack of sufficient coverage at a
particular locus will cause Veridical to be unable to report any significant results. A coverage of at
least 20 reads should be sufficient.", but they do not provide evidence for this assertion. This is an
important question given that low-expressed genes are thus likely to be systematically
under-represented in the results of Veridcal, and this should be commented on somewhere in the
paper.
8. It would be good if the authors provided Sanger validation of at least some of the mis-splicing
events reported in the paper.
9. The input format for Veridical is described as "This input format most easily accepts formatted
output from the Shannon Pipeline." Why not allow VCF files and filter them for potential splice
variants informatically prior to Veridcal analysis? It was unclear to me how the variants are to be
selected and whether Veridical can be easily used outside of the Shannon pipeline?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
1 Comment

Author Response
Peter Rogan,
Posted: 27 Mar 2014
We really appreciate your constructive comments. In particular, we have revised figure 1 as you
suggested. Furthermore, we have endeavored to clarify the methods by referencing every
corresponding equation pertaining to each informal description of a methodological principle. All
references to figures pertain to the first version of the manuscript.
"It is unclear to me why a linear regression model was used to show the performance of the
method. The authors could provide timings from real runs."
All data points in Figure 3 (a) consist of data from actual runs. We did not conduct a
sufficient number of large-scale runs to accurately determine performance and believe that
the regression model provides information for users who wish to use the software in that
context.
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context.
"The input format for veridical is described as “This input format most easily accepts
formatted output from the Shannon Pipeline.” Why not allow VCF files and filter them for
potential splice variants informatically prior to veridcal analysis? It was unclear to me how
the variants are to be selected and whether veridical can be easily used outside of the
Shannon pipeline?"
It would be prohibitively difficult for a user and cumbersome to attempt to add such support.
The Shannon Pipeline and most other splicing analysis software accept variant call format
(VCF) input and outputs their own custom format. VCF is very poorly suited for the
annotation of detailed splicing information. The position of the variant is not necessarily the
same as the affect splice junction coordinate. While it is possible to label the junction using
custom fields in the VCF “INFO” column, the format is not standardized; it would be specific
to the particular software used, and thus provides no real advantage over the Shannon
pipeline output.
This would become feasible if the community were to agree upon a standard definition of
custom fields; this concept could be generalized to other scenarios in which both a variant
and one (or more) other associated coordinates (in this case, a splice site, but elsewhere,
perhaps the site of some specific interaction). This process would ultimately require an
explicit definition of the content and schema for such additional fields, and would need to
solicit views from the community to ensure widespread adoption. We would be interested in
contributing to this endeavor.
"It would be interesting to see a plot on the relationship of the p-values called by Veridical
and the sequencing depth covered."
We have conducted a preliminary comparison of p-values for specific evidence types and
splicing consequences vs. coverage per exonic base (the coverage of the gene divided by
the length of the pertinent exon) and found that the results were quite difficult to interpret.
We suspect that this could be explained by the fact that, due to significant intron inclusion,
normalizing by exonic length is not really appropriate. Cryptic sites and alternative splicing
make direct comparison of these values difficult to compute.
"How does Veridical decide which sequence variant is causative if there are multiple
variations located in the vicinity of a given mis-spliced exon?"
Veridical does not currently address cases in which multiple independent variants pertain to
the same splice site. In such a case, each variant is analyzed independently. Based on
Mendelian disorders, we have rarely observed multiple independent variants alter the
strength of the same splice site, and in any case, the phase of these variants is unknown, so
they could reside on different chromosomes.
"I am a little unclear on the use of control samples vs experimental samples. Assuming the
experimental samples come from different individuals, what is the reason to assume that
they will have the same distribution of splice mutations? And given that one finds dozens of
splice variants in normal individuals, what exactly is meant by a control sample? Will not
control samples also have lots of splice mutations? How does the method deal with this?
And if we are dealing with cancer samples, why not user a paired control to detect
F1000Research
Page 21 of 33

F1000Research 2014, 3:8 Last updated: 09 MAY 2014

And if we are dealing with cancer samples, why not user a paired control to detect
cancer-specific mutations? In light of this, the statement “Maximizing the set of control
samples, while computationally more expensive, increases the statistical robustness of the
results obtained.“ Does not appear to be supported by evidence presented in the
manuscript."
Control samples consist of all non-variant containing (NVC) tumour samples (relative to the
variant being analyzed) and normal samples. In the examples shown in the paper, we
maximized the number control samples used (106 normal samples and, in general, over
400 NVC samples). Control samples do indeed contain splicing mutations and this is a
strength of our statistical paradigm. We term them control samples, because we consider
their read distribution to correspond to that expected from the null hypothesis, as they do
not contain the specific variant in question. The “noise” introduced by these splicing variants
in control samples ensures that we are testing the variant containing samples against
samples with many, distinct, splicing mutations. Thus, the greater the number of samples,
the smaller the batch effects, which makes the method more reliable. While the normal and
tumor DNA sequencing data was paired to call somatic variants, we do not require paired
controls for the RNA-Seq data. In fact, TCGA does not provide such data. Since we initially
designed the software for the task of analyzing their dataset, we did not wish to assume that
paired RNA-Seq data was available.
"It would be good if the authors provided Sanger validation of at least some of the
mis-splicing events reported in the paper."
We do not have access to the TCGA tumour samples used. While TCGA performed Sanger
validation of a small subset of their variants, none of the variants validated by Veridical had
any associated Sanger sequencing data.
"It would be interesting to see a comparison of the distribution of Ri values and results of
Veridical analysis?"
The variants predicted by the Shannon splicing mutation analysis pipeline exhibit changes
in information content (ΔRi). The change in information content of a splice site is directly
related to the thermodynamics of the binding event (Schneider, 1997) and therefore the
strength of the splice site (Rogan et al., 1998; Rogan et al., 2003). Therefore, one would
expect ΔRi to be highly predictive of valid splicing variants, where cryptic sites are expected
to result in increased splice site strength, and natural sites would be expected to be
weakened.
The median ΔRi for cryptic variants in the set of pre-Veridical variants (those variants called
as somatic mutations and predicted by the Shannon Pipeline to affect mRNA splicing) was
2.6 bits, while the median for validated variants was 2.38 bits. For non-cryptic variants the
pre- and post-validation median ΔRi values were -2.52 and -3.18 bits, respectively.
The information content of cryptic variants actually decreased slightly in the validated set.
This likely is related to other factors, such as the initial strength of the natural site and the
exon length, which are not accounted for by this analysis. However, the average information
content of natural sites did decrease, as expected. The reason for the decrease not being
more substantial, again, is likely due to the involvement of other factors, such as the
distance of the variant to the natural site – which impacts its R value. We have refrained
F1000Research
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distance of the variant to the natural site – which impacts its R i value. We have refrained
from including this discussion in the manuscript, since there is no requirement per se for
Veridical to be used with the Shannon Pipeline. An explicit definition of the required input
format is provided in the paper.
Competing Interests: No competing interests were disclosed.

Liliana Florea
McKusick-Nathans Institute of Human Genetics, Johns Hopkins University, Baltimore, MD, USA
Approved with reservations: 07 March 2014
Referee Report: 07 March 2014
The authors describe a method and the associated software, Veridical, for assessing the effects on
pre-mRNA splicing of predicted splicing-affecting mutations. To do so the program compares splicing
effects, measured by the supporting read counts, in variant-containing (disease) samples against a
distribution derived from very large numbers of 'normals', either normal tissue from the same individual or
samples from healthy individuals.
The idea is ingenious and novel as applied to mutations affecting splicing, although not in general (see
VAAST [Yandell et al. 2011], which exploits the availability of large numbers of samples to identify likely
deleterious variants; it is also the premise for the HapMap and 1000 Genomes projects). The software is
fast and practical, being able to test thousands of variants in hundreds of samples within hours. This is the
first software of its kind, and if accurate it will be a very valuable resource for clinical genomics.
That being said, while the article provides proof-of-concept and clearly demonstrates the potential of the
tool with specific examples, there are several missing pieces that are needed to provide the readers with
a view of its overall performance and limitations and to help them use it effectively.
Major comments:
1. The article shows numerous positive examples, however there is no indication of the tool's
performance in general. The authors should include the results from running the tool on a full data
set, to give potential users an idea of the expected outcome.
Also, several other tools (e.g., MATS, Miso, SpliceTrap) have been developed for the related
problem of discovering alternative splicing events and comparing them among samples. MATS in
particular, allows differential splicing analyses with multiple replicates. Ideally the paper would
include a comparison with MATS on the data set analyzed; this comparison is informative even if
MATS is used with only a subset of the samples.
2. The method uses the YJ-transformed distribution of supporting read counts across the 'normals' to
determine a p-value for the variant, and thus judge its significance and impact on splicing. This is
an interesting concept that assumes that with large numbers of 'normals' sample and batch effects
will even out; hence, large numbers of samples are required to ensure accuracy. Since these are
absolute (non-normalized) counts, however, the method may not work if the variant sample is
obtained with a different method, e.g. by rRNA depletion of total RNA whereas most normal
samples would come from polyA+ libraries. The authors should clearly discuss this and other
possible limitations of their approach.
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samples would come from polyA+ libraries. The authors should clearly discuss this and other
possible limitations of their approach.
3. Related to the above, the authors mention on several occasions the difficulty in identifying intron
inclusion (II) events, in particular the large number of false positives. Indeed, IIs are generally
difficult to predict due to the presence of intronic reads ('noise') from unspliced RNA. The levels
can vary from sample to sample and across the genome, depending on the sample preparation,
gene expression level, splicing efficiency, etc. By comparing read counts exclusively among
samples and without taking into account the gene- or genome-level background, Veridical is likely
to produce many false positives.
In particular, the 14 supporting reads in the left intron on Figure 4 seem hardly sufficient to indicate
an II event, all the more as there is a larger number of reads in the neighboring intron (not predicted
to be II). The authors should provide other type of evidence for this event.
4. The mathematical formulas for the various classes of supporting reads and their locations (page 4,
continued on page 6) are hard to understand. It would greatly help the readers to include a figure
showing schematically the event and read location with respect to the introns and exons.
Minor comments:
1. As another reviewer pointed out, the software requires a registration to obtain a temporary license
for 30 days, after which the availability and terms of use are unclear. This mode of distribution is
not a problem, but the terms should be clearly stated in the manuscript. Also, this is a stand-alone
software and not a web tool as implied by the article.
2. The authors use the term 'cryptic' splice sites throughout the manuscript (I assume meaning
'aberrantly activated'), but some of the events discovered could be alternative exon ends. It would
be helpful to clarify in the context.
This is a potentially very powerful and useful tool. I gave the article an 'Approved with reservation'
because it is critical to include results in the aggregate to complement the showcased examples, as well
as to discuss its limitations. I will gladly change once these few issues are addressed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Competing Interests: No competing interests were disclosed.
1 Comment

Author Response
Peter Rogan,
Posted: 27 Mar 2014
We greatly appreciate your remarks and useful suggestions. All references to figures pertain to the
first version of the manuscript.
First, we address your comments regarding VAAST and de novo exome annotation software
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First, we address your comments regarding VAAST and de novo exome annotation software
packages. VAAST uses a feature-based, maximal likelihood, approach to identify variants
suspected to be pathogenic. While Yandell et al. present a general, and indeed very useful
method, it is very different from Veridical in two key respects. Most importantly, Veridical does not
aim to identify putatively pathogenic variants, but rather, to confirm existing in silico predictions
thereof. Although it is not designed for this purpose, one could envision using the likelihood
approach used by VAAST to extract solely splicing variants, annotating them, and then confirming
these variants using Veridical with corresponding RNA-Seq data (assuming such data exists).
Veridical is the only software available for statistical validation of splicing mutations. While both
programs prioritize variants, their goals are rather dichotomous. Similarly, Veridical depends upon
the use of an (ideally conservative) exome annotation. We do infer exon skipping events (i.e.
alternative splicing) de novo, but only to catalog dysregulated splicing “phenotypes” due to
genomic sequence variants. Since we rely upon existing annotations, improvements in this area
will serve to benefit Veridical and complement it well. In many ways, our parsimonious approach
was possible precisely because the problem we address is quite a lot easier to address than de
novo alternative splicing inference. We are not suggesting that Veridical be used to analyze all
variants, resulting from exome or whole-genome sequencing experiments. The Shannon Pipeline,
which predicts candidate variants, contains several default or modifiable filters which can limit the
number of candidates input to Veridical. We are suggesting that our approach be coupled to
existing approaches to act as an a posteriori, hypothesis-driven, check on the veridicality of
specific variants.
We consider alternative splicing to be a different problem, for the following reasons. The authors
state: “MATS calculates a P-value for each exon isoform by comparing the observed posterior
probability with a set of simulated posterior probabilities from the null hypothesis.” We do not
simulate posterior probabilities; we calculate them directly from the distribution of control samples,
which represent the null hypothesis. Further, MATS requires the user to set uniform thresholds for
all alternative splicing events, which in our case, may vary between variants (i.e. inactivating
versus leaky mutations). Finally, neither MATS, nor Miso or SpliceTrap provide any means of
analyzing novel isoforms created by the activation of cryptic splice sites.
We appreciate your insightful summary of our underlying statistical methodology and appreciate
the limitations of our statistical inference method. It is certainly the case that the use of different
RNA-Seq protocols could prove problematic. Veridical is intended to be used with RNA-Seq data
from the same individual as matched DNA-Seq data. We assume that the control RNA-Seq data
are generated with comparable sequencing protocols. This has been articulated in the Discussion.
We agree that levels of intron inclusion and alternative splicing can be highly variable across
samples, due to factors extrinsic to the mutation itself. Such variability is a significant contributory
factor to the production of transcriptomic “noise”. Given that statistically significant levels of intron
inclusion were observed across all control samples, the prevalence of adjacent intron inclusions
(which is not uncommon, per se), does not weaken the inference that the predicted splicing
mutation increases the levels of intron inclusion. However, in such cases, the statistical threshold
to achieve significance would be higher. A recent analysis indicates that p-value thresholds of
0.005 to 0.001 are appropriate (Johnson, 2013). Our statistical approach tacitly accounts for this
and indeed greater levels of such “noise” could actually increase the statistical utility of our
computation. Because of a wide degree of variation of intron inclusion in both normal and tumor
transcriptomes, we deliberately elected against normalizing gene level expression in the program.

Regarding the specific example cited, the 14 intronic reads in the sample containing the variant in
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Regarding the specific example cited, the 14 intronic reads in the sample containing the variant in
the read-abundance category (Figure 4 (A)) are contrasted with the per sample mean of 4.051
reads across all non-variant-containing tumours and normal samples in this intron (i.e. the totality
of control samples, which results in a p-value of 0.04. We agree that this is not a strong result, and
would not permit us to reject the null hypothesis had the threshold significance level been reduced
to ≤ 0.01 (which the user is free to stipulate).In this particular case, the variant is still strongly
validated, due to the presence of junction-spanning, exon skipping reads (that are absent from all
of the control samples). We do not stipulate that the predicted mutation have only one abnormal
read type, but rather, that the test assesses each consequence separately. We suggest that the
corroborating evidence be taken together in support of variant-induced missplicing. Furthermore,
junction-spanning exon skipping is, in general, rarer than intron inclusion in these data.
Nevertheless, we do show examples of read-abundance tests for intron inclusion that achieve a
significance level of < 0.01, such as within TMTC2 in Figure 6(C). As you point out, intron inclusion
patterns also vary by intron and there are a large number of such intron inclusion reads in the
downstream intron in Figure 4(A). However, in our entire set of predicted splicing mutations, we did
not find any pertaining to the intron between exons 12 and 13. The observed increased intron
inclusion between exons 12 and 13 may be related to the weak (5.2 bit) donor (5’) splice site in
exon 12. In fact, substantial intron inclusion was expected in intron 11, due to the minimal strength
of the exon 11 donor of 2.1 bits.
Regarding the comment concerning cryptic sites, we always mean non-canonical splice sites
activated by sequence-level variation, which are distinctly different from tissue-related alternatively
spliced isoforms lacking one or more constitutive exons. We and others have reported numerous
examples of common SNPs inducing cryptic splice site activation, which could result in the
annotation of accordingly altered transcripts.
It is unfortunate that Veridical had to be categorized as a “web tool”. We would have preferred to
indicate that the program is a standalone-tool. F1000Research does not provide this category,
even though other standalone programs have been published by the journal with the Web Tool
designation. In the Web Tools category, the journal guidelines require that we provide a set of
examples (complete with input and output files) representing the range of results that are obtained
with the software. Therefore, providing a full analysis of the complete TCGA breast cancer dataset
is beyond the scope of this paper. It will be presented elsewhere.
We believe that the statements in the manuscript's conflict of interests section are sufficient to
describe the terms of use. We have added the requested details on Veridical.org, both indicating
its duration and instructions for obtaining longer-term access to this software.
Competing Interests: No competing interests were disclosed.

Francesc Xavier Roca
Division of Molecular Genetics and Cell Biology, Nanyang Technological University, Singapore,
Singapore
Approved: 28 January 2014
Referee Report: 28 January 2014
This manuscript describes a new computational tool named Veridical, which detects mutant-allele specific
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This manuscript describes a new computational tool named Veridical, which detects mutant-allele specific
splicing changes from large RNAseq datasets. This outstanding tool appears very useful to screen the
wealth of transcriptomic data for effects in splicing due to mutations in disease samples, and I think that it
will potentially be of interest for many if not all such RNAseq-based studies. In addition, this could spur
further efforts to derive similar tools with improved efficiencies. Use of this method should help establish
the importance of aberrant splicing in disease as well as the effects of genomic mutations at the RNA
level. I only have two comments, that do not diminish my overall rating of this work as of high value:
1. I personally disagree with the widespread use of the word “validation” in the title, abstract and text.
Authors describe Veridical as a tool to “validate” DNA sequence variants that alter splicing. Indeed,
I think that this tool provides an “association” between the variants and splicing, but not a formal
proof of their connection. As the genomic and RNA samples usually come from different individuals
with many confounding variables, the possibility that the splicing changes arise from factors other
than the individual DNA mutations cannot be ruled out. In other words, changes in the levels of
trans-acting splicing factors could account in part or totally for the splicing changes across
samples. The statistical tests properly conducted in Veridical are designed to minimize such
possibility but do not rule it out. In addition, the inherent noisy nature of RNAseq datasets also
prompts for caution in the conclusions. To me, the direct proof that a DNA mutation changes
splicing of its pre-mRNA can only be provided using minigenes and cell transfection (or in vitro
splicing), in which the substrate sequences and cellular context are under almost absolute control.
Indeed, the Veridical method is reminiscent of GWAS (Genome-Wide Association Studies), in
which the genotype in the DNA, wild-type or mutant, is associated to its phenotype, such as normal
versus disease (or other traits) in GWAS, or normal versus aberrant splicing in this study. Thus, for
me Veridical provides strong associations – but not validations – between DNA mutations and their
effects on splicing.
2. As mentioned briefly at the beginning of Discussion, Veridical has built-in prediction tools to
prioritize the mutations that are more likely to affect splicing, such as those mapping to splice sites.
Even if other sources and tools are cited, a more extensive explanation of these components of
Veridical would help the reader/user.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
1 Comment

Author Response
Peter Rogan,
Posted: 27 Mar 2014
We greatly appreciate your review of this paper.
Regarding our use of the term “validation”, we understand that in silico validation is not comparable
to in vitro or in vivo validation assays. That said, we would like to elaborate. The DNA and RNA
samples were matched from the same individual, which is not the case for many in vitro assays, i.e.
mini-gene expression analysis by reverse transcription followed by PCR. The very large set of
F1000Research
Page 27 of 33

F1000Research 2014, 3:8 Last updated: 09 MAY 2014

mini-gene expression analysis by reverse transcription followed by PCR. The very large set of
controls used in our analysis is also atypical in experimental validation of proposed mutations.
When results are obtained that are statistically significant, it is conventional to refer to them as
“validating”. Even if DNA-Seq and RNA-Seq data were not matched from the same individual,
Veridical would still determine if known splicing mutations were expressed in a known subset of
tumors, however we would instead refer to this as "corroborating".
The comparison with GWAS is inappropriate: we are not comparing means of distinct case and
control distributions; rather we are computing the read distribution from the control samples and
determining the probability that the mutation bearing sample falls within that distribution.
Additionally, the initial hypothesis in a GWAS is quite vague. Thus, the resultant associations are
not of the same category as those provided by Veridical. While Veridical does indeed validate the
splicing consequence observed, when we say that it validates the mutation we do only mean that it
strongly corroborates the mutation as a causative agent of the splicing consequence. The
responsibility to decide if the p-value reported by the program is sufficient is left up to the user, who
should avoid incorrect post hoc ergo propter hoc arguments.
Our reference to prioritization of variants for subsequent verification is based upon the result of
Veridical's statistical tests. We explicitly mention that the software is not well suited for the analysis
of raw output from genome-scale analyses, and that filtering should be performed a priori, as we
conducted, with a separate Perl script, which is available with Veridical.
Competing Interests: No competing interests were disclosed.

Stefania Bortoluzzi
Department of Biology, University of Padova, Padova, Italy
Approved with reservations: 27 January 2014
Referee Report: 27 January 2014
The paper “Validation of predicted mRNA splicing mutations using high-throughput transcriptome data” by
Viner et al. presents Veridical, a new software for the interpretation and validation of genetic variants
identified by DNA sequencing that alter mRNA splicing, leveraging RNA-seq data. The method is based
on statistical comparisons of the normalized read counts of abnormally-spliced RNA species in mutant
versus non-mutant tissues.
Actually, the interpretation of genetic variants is a difficult and key issue in current research.
The integration of genomic and transcriptomic data, namely the use of RNA-seq-based transcriptome
characterization as a “molecular phenotype” of cells is useful and meaningful.
The software is standalone (not a web-tool) and it is completed by perl scripts, facilitating data
management.
The manuscript declare that “Veridical and its associated software programs are available at:
www.veridical.org”.
Actually, Veridical is commercially available to the scientific community. A trial version lasting 30 days can
be downloaded by the website, but in order to obtain binaries, the website requests a registration with an
institutional email address - they reserve the right to deny access to users who register with third-party
mail servers (Gmail, Yahoo, Hotmail, etc.).
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mail servers (Gmail, Yahoo, Hotmail, etc.).
No pricing information is included in the manuscript and, more importantly, in the webpages accessible to
download the software, either before or after registration.
After downloading the software, I was not able to find R scripts that can be useful to generate some plots,
as indicated in the manuscript.
Saying that, the paper is written in a clear language and it is quite complete.
I propose a few revisions that in my opinion can improve the manuscript readability and clarity.
Introduction
Line 13 (minor): indicate which hereditary disease (colon cancer?).
Methods
2nd Par, Line 5 (minor): “Maximising” is used, but probably the meaning is “increasing” (the number
of).
Figure 1 (major): I feel that the info provided by points C and D is trivial, whilst point A's images,
sentences and legends can be improved. Figure 1 C and D shows simply examples of reads that
are mapped continuously and discontinuously to the reference genome. I think that every potential
user of this type of software known well this concept. On the other hand, regarding A and B (upper
part of the figure) there is not clear correspondence between the text in the legend and the image,
and between the image and the text below (the arch overlap the point A in the figure B, whereas
the text says "reads between A and B").
In general, in many cases in the manuscript, the correspondence between legend and figure can
be improved, by indicating more clearly the points specific sentences in the legend refer to.
Regarding this issue, for instance in Figure 4 I can see indicated neither the “exon 12” nor the “14
reads” mentioned in the legend. Please indicate (using colors, boxes, arrows or overlapping text)
key elements in the figure, and revise all figures using the same criterion.
Page 5 (minor): Consider revising the sentence “Furthermore, this transformation allowed us to
avoid the use of non-parametric testing, which has its own pitfalls regarding assumptions of the
underlying data distribution”, since normally it is assumed that parametric tests ground on
assumptions on data distributions, but non-parametric tests by definition can be used without
information about data distribution.
End of the next paragraph (major): “It is important to realize, therefore, that the p-values given by
Veridical are much more robust when the program is provided with a large number of samples.”
This is a pretty clear concept. Please, indicate a general rule to the user/reader: How many
samples are required? Setting a reasonable minimum can be more useful for experimental design
than saying the larger the sample size the most robust the result.
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Results
I have two important criticisms about the Results section:
1. The section is not organized in paragraphs, and mixes performance info (run time using different
number of samples and variants) with example results.
2. Not clearly saying how these results were obtained. This is important to guarantee repeatability.
(Major) I propose to reorganize the results (considering skipping less important examples; retain
surely Fig. 4 and 6) and insert a first paragraph providing information about the dataset used for
variants validation (how many samples, how many controls) and about the variant calling (BAM
files can be obtained with different settings and criteria and the same apply to calling and filtering of
variants). Moreover, please explain how RNA-seq data are treated, and particularly how they are
normalized to guarantee cross-samples comparability.
(Major) Also, a brief discussion about the impact of disease samples not carrying the given
mutation can be useful, as well as regarding the possibility that a tumour sample not carrying the
considered variant can present altered transcriptome since other variants (or factors) impact on the
“molecular phenotype”.
Figure 4 (minor): Please comment about the possible existence of intronic transcripts (totally
unknown or also annotated in Ensemble, but not displayed in the more conservative RefSeq
annotations).
Figure 5 (minor): Please define better the measure “Read−Abundance Total Intron Inclusion”.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Competing Interests: No competing interests were disclosed.
1 Comment

Author Response
Peter Rogan,
Posted: 27 Mar 2014
Thank you for your constructive comments. Regarding the R program, it is embedded within a Perl
script to facilitate expeditious parameter and data parsing. All of our figures were generated using
the Perl script, which, in-turn, invokes the R script. The program used to generate the histograms is
called: VeridicalHist.pl. The invocations of this program are provided in the Perl program
documentation on www.veridical.org. We have clarified this in the revision of the manuscript. We
will update this web page to include pricing information and details about trial access to the
software.
The requirement to provide an institutional email address is quite ubiquitous across a number of
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The requirement to provide an institutional email address is quite ubiquitous across a number of
academic disciplines, including many fields of informatics. In bioinformatics, for example,
ANNOVAR requires non-profit users to register an address and HGMD does as well. ChemAxon,
software for cheminformatics requires this. In astroinformatics, Sloan Digital Sky Survey III
(SDSSIII) also requires an institutional email. These examples are represent a fraction of the
numerous scientific websites that request such emails. We consider it a professional courtesy to
provide legitimate email information, and reserve the right to disapprove addresses of individuals
who seek to mask their identity, which may enable them to avoid acknowledging the provenance of
the software.
We specifically address each of your other comments below. All references to figures pertain to the
first version of the manuscript.
"Line 13 (minor): indicate which hereditary disease (colon cancer?)."
López-Bigas et al. (2005) conducted a general analysis using the complete sets of
SwissProt genes and OMIM known disease genes. Their mathematical model does not
depend upon any specific hereditary disease. Nevertheless, certain genes have been
demonstrated to exhibit very high frequencies of splicing mutations ( ATM, NF1).
"2nd Par, Line 5 (minor): “Maximising” is used, but probably the meaning is “increasing” (the
number of)."
This has been corrected.
"Figure 1 (major): I feel that the info provided by points C and D is trivial, whilst point A's
images, sentences and legends can be improved. Figure 1 C and D shows simply examples
of reads that are mapped continuously and discontinuously to the reference genome. I think
that every potential user of this type of software known well this concept. On the other hand,
regarding A and B (upper part of the figure) there is not clear correspondence between the
text in the legend and the image, and between the image and the text below (the arch
overlap the point A in the figure B, whereas the text says "reads between A and B")."
This has been revised accordingly.
"In general, in many cases in the manuscript, the correspondence between legend and
figure can be improved, by indicating more clearly the points specific sentences in the
legend refer to. Regarding this issue, for instance in Figure 4 I can see indicated neither the
“exon 12” nor the “14 reads” mentioned in the legend. Please indicate (using colors, boxes,
arrows or overlapping text) key elements in the figure, and revise all figures using the same
criterion."
In general, we provide exon numbers for reference and to allow for future exon identification.
While we specifically describe in the captions which exon contains the variant and relate this
to the exon number, we agree that graphical indications of key figure elements within IGV
screenshots could improve the clarity. These figures have been revised accordingly.
"Page 5 (minor): Consider revising the sentence “Furthermore, this transformation allowed
us to avoid the use of non-parametric testing, which has its own pitfalls regarding
assumptions of the underlying data distribution”, since normally it is assumed that
F1000Research
Page 31 of 33

F1000Research 2014, 3:8 Last updated: 09 MAY 2014

assumptions of the underlying data distribution”, since normally it is assumed that
parametric tests ground on assumptions on data distributions, but non-parametric tests by
definition can be used without information about data distribution."
In this sentence, we are not referring to the ubiquitous assumption of an underlying normal
distribution, which is indeed not required for non-parametric tests. Instead, the reference is
to, other, lesser known, assumptions that are tacit in most non-parametric methods. The
citation we provide (Johnson, 1995) refutes the commonly-held notion that non-parametric
tests make no assumptions about the underlying data distribution, and describes numerous
pitfalls that can occur when using non-parametric methods. For example, the author
articulates a particular assumption implicit in a comparison of means via the Mann-Whitney
test which actually requires that, “the two distributions are identical, in shape and scale,
differing only in their means. This assumption can be harder to justify than the asymptotic
normality demanded by the t test, and is rarely evaluated.”
"End of the next paragraph (major): “It is important to realize, therefore, that the p-values
given by Veridical are much more robust when the program is provided with a large number
of samples.” This is a pretty clear concept. Please, indicate a general rule to the
user/reader: How many samples are required? Setting a reasonable minimum can be more
useful for experimental design than saying the larger the sample size the most robust the
result."
The revised manuscript describes the procedure and criteria for determining the number of
control samples needed.
"The section is not organized in paragraphs, and mixes performance info (run time using
different number of samples and variants) with example results."
The profiling information and example results are more clearly demarcated in the revision.
"(Major) I propose to reorganize the results (considering skipping less important examples;
retain surely Fig. 4 and 6) and insert a first paragraph providing information about the
dataset used for variants validation (how many samples, how many controls) and about the
variant calling (BAM files can be obtained with different settings and criteria and the same
apply to calling and filtering of variants). Moreover, please explain how RNA-seq data are
treated, and particularly how they are normalized to guarantee cross-samples
comparability."
We now elaborate upon experimental protocols, processing, and data providence. The
details of the RNA-Seq data and BAM file generation can obtained from the TCGA
consortia, which generated them, specifically in the supplementary methods of Koboldt et
al. (2012). All of our data input directly into Veridical are available, and even the program
used to generate the histograms is provided. This ensures that all of our results are
reproducible.
The input data were obtained by analyzing the original TCGA dataset with the Shannon
pipeline, as the paper describes. The pipeline has been published in a peer-reviewed
context and is also available on a trial basis. The details of the TCGA analytical results
obtained with the Shannon pipeline are considerable in length, putting them beyond the
scope of this paper and will be described elsewhere.
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scope of this paper and will be described elsewhere.
The journal guidelines concerning “web tools” state: “The article should provide examples of
suitable input data sets and include an example of the output that can be expected from the
tool and how this output should be interpreted.” The examples shown are representative of
the splicing analysis outcomes present in the full TCGA analysis. The examples provided in
this paper were designed to illustrate the capabilities of Veridical and are not an attempt to
forge biological conclusions of this large dataset.
"(Major) Also, a brief discussion about the impact of disease samples not carrying the given
mutation can be useful, as well as regarding the possibility that a tumour sample not
carrying the considered variant can present altered transcriptome since other variants (or
factors) impact on the “molecular phenotype”."
We provide in Table 2 the read counts for non-variant containing tumour samples, and for
the variant containing samples. We acknowledge that cancer gene expression results in a
gross dysregulation of mRNA splicing thereby causing the presentation of the altered
transcriptome. This was a motivating factor behind our choice of statistical method.
"Figure 4 (minor): Please comment about the possible existence of intronic transcripts
(totally unknown or also annotated in Ensemble, but not displayed in the more conservative
RefSeq annotations)."
If such exons exist, which are annotated as introns by RefSeq, and are actively transcribed
in normal or breast cancer tissues, the large number of control samples will reflect this and
such events will accordingly not trigger statistically significant intron inclusion events. We
have added a comment to the Discussion reflecting this.
"Figure 5 (minor): Please define better the measure “Read−Abundance Total Intron
Inclusion”."
This has been addressed in the revision.
Competing Interests: No competing interests were disclosed.
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